U.S. Biotech Stock News

Corcept Therapeutics (CORT) has received U.S. Food and Drug Administration approval for Lifyorli, to be used with nab paclitaxel in adults with platinum resistant ovarian, fallopian tube, or primary peritoneal cancer. See our latest analysis for Corcept Therapeutics. Corcept’s latest FDA approval lands after a volatile stretch, with a 12.71% 7 day share price return and a 6.78% 30 day share price return, alongside a 1 year total shareholder return of 58.53% decline. Meanwhile, 3 and 5 year...

What Mastercard’s recent share performance signals for investors Mastercard (MA) has drawn attention after recent share performance, with the stock showing a 2.0% gain over the past day but declines over the week, month, past 3 months and past year. See our latest analysis for Mastercard. The recent 1 day share price gain contrasts with weaker 1 month and year to date share price returns. At the same time, 3 and 5 year total shareholder returns in the high 30% range point to a longer term...

New independent cost impact model evaluates Indivior's extended-release buprenorphine (SUBLOCADE) in U.S. correctional facilities. The model suggests SUBLOCADE, a monthly injectable for opioid use disorder, may meaningfully cut staff time and related costs versus other treatments. Findings, published in a peer reviewed journal, highlight potential operational benefits and treatment access gains for jails and prisons. For investors watching Indivior Pharmaceuticals (NasdaqGS:INDV), this...

EQT Corporation recently completed an upsized cash tender offer for multiple series of senior notes maturing between 2027 and 2031, raising its aggregate purchase cap to US$1.40 billion and adjusting sub-caps across key 2029 issues. This move signals active balance sheet management as EQT retires higher-cost debt, potentially reshaping its interest expense profile and financial flexibility. We’ll now examine how EQT’s expanded US$1.40 billion debt tender offer affects the company’s...

Wondering whether CubeSmart's current share price still offers value, or if most of the opportunity has already been priced in? This article breaks down what the numbers actually say about the stock. CUBE has had a mixed run recently, with a 3.4% decline over 7 days, a 12.7% decline over 30 days, a 1.4% gain year to date, and an 11.4% decline over the last year, which can change how the market views its risk and return profile. Recent coverage has focused on CubeSmart's share price moves and...

DTE Energy (DTE) drew fresh attention after its recent trading session, with the stock closing at $146.06 and short term returns showing mixed moves over the past week, month and past 3 months. See our latest analysis for DTE Energy. Looking beyond the latest move, DTE Energy’s share price return of 12.0% year to date and 12.5% over 90 days points to building momentum. The 1 year total shareholder return of 9.2% and 3 year total shareholder return of 48.6% reflect a solid longer term outcome...

Starwood Property Trust (STWD) has been drawing attention after recent share price moves, with the stock closing at $17.37. Investors are weighing this against its income profile and diversified real estate financing model. See our latest analysis for Starwood Property Trust. The recent 1-day share price return of 1.94% comes after weaker short term moves, with 30 day and year to date share price returns of 2.47% and 5.70% declines. However, the 3 year total shareholder return of 32.79%...

Enerpac Tool Group Corp. recently reported its second quarter fiscal 2026 results, showing higher sales of US$154.81 million but lower net income of US$16.31 million year over year, updated its full‑year 2026 guidance, and completed a US$65.9 million share repurchase program initiated in October 2025. Management also highlighted an active pipeline of potential acquisitions, backed by low leverage of 0.6x and an untapped revolver, signaling that disciplined M&A remains a central element of...

Home Depot (NYSE:HD) has appointed Dr. Franziska "Fran" Bell as executive vice president and chief technology officer. Dr. Bell will lead enterprise-wide technology, digital product management, and AI efforts for the company. She brings experience from senior technology and AI roles at Ford, BP, and Uber. Home Depot, a major home improvement retailer serving DIY customers and professionals, is moving further toward tech-driven retail operations with this leadership change. Retailers...

If you are wondering whether Seagate Technology Holdings is still offering value after a strong run, the starting point is to understand how the current share price lines up against a few different valuation checks. The stock last closed at US$362.43, with returns of 26.0% year to date and 332.1% over 1 year, but also short term pullbacks of 10.3% over 7 days and 11.1% over 30 days that may have shifted how the market is thinking about risk and reward. Recent attention on Seagate has been...

StepStone Group (STEP) is back on investor screens after recent share price swings, with the stock up over the past month but lower across the past 3 months and year to date. See our latest analysis for StepStone Group. The recent rebound, including a 7.81% 1 month share price return from a last close of US$46.51, comes after a much weaker 90 day share price return of a 27.99% decline. The 3 year total shareholder return of 114.48% contrasts with a 1 year total shareholder return of an 8.57%...

If you are wondering whether Pegasystems is offering fair value at its recent price, it helps to break the story into what the share price has done, what has been in the headlines, and how that stacks up against a structured valuation checkup. The stock last closed at US$41.48, with returns of a 6.5% decline over 7 days and a 5.1% decline over 30 days, while still showing a 19.6% gain over 1 year and 73.4% over 3 years, and a 26.0% decline year to date and a 29.0% decline over 5...

Abbott Laboratories is integrating its Precision Oncology portfolio into Flatiron Health's OncoEMR platform used by a wide U.S. oncology network. The move brings Abbott's advanced cancer diagnostics directly into clinicians' electronic workflows, aiming to simplify ordering and results review. This development follows Abbott's expansion into cancer diagnostics through its deal with Exact Sciences. For investors tracking NYSE:ABT, this news sits against a mixed share price picture. The stock...

Wondering if DRDGOLD at around US$27.65 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price might imply. The stock has returned 1.7% over the last 7 days, while the 30 day return sits at a 28.9% decline, against an 8.8% decline year to date and an 81.5% return over the past year, with a very large 3 year and 226.1% 5 year return. Recent coverage has focused on DRDGOLD as part of broader gold and precious metals...

Recent performance snapshot for D.R. Horton D.R. Horton (DHI) has seen its share price move lower recently, with a 1 day return of a 1.2% decline, a 7 day return of a 4.5% decline, and a 1 month return of a 17.4% decline. Over longer periods, the stock shows a past 3 month return of an 8.9% decline, a year-to-date return of a 9.1% decline, and a 1 year total return of 5.5%, alongside a 3 year total return of 39.1% and a 5 year total return of 50.4%. See our latest analysis for D.R...

If you are wondering whether Elevance Health's current share price reflects its true worth, this article will walk you through what the numbers actually say. Recently, the stock has retreated, with returns of a 1.5% decline over 7 days, an 11.0% decline over 30 days, a 19.6% decline year to date, and a 33.1% decline over the past year from a last close of US$284.79. These moves have arrived alongside ongoing sector attention on large managed care names and investor focus on how insurers are...

In March 2026, Academy Sports and Outdoors, Inc. reported fourth-quarter sales of US$1,718.47 million and net income of US$133.69 million, issued full-year 2027 guidance, and confirmed completion of a share repurchase program totaling 5,089,876 shares for US$263.51 million. While full-year sales edged up to US$6,053.41 million but net income softened to US$376.77 million, the combination of higher fourth-quarter earnings per share and ongoing buybacks highlights how capital allocation and...

Visa (V) continues to attract attention from investors after recent share price weakness, with the stock down about 6% over the past month and 15% over the past 3 months, which has sharpened the focus on its fundamentals. See our latest analysis for Visa. Visa's recent share price weakness, including a 6.4% 30 day share price return decline and a 15.3% 90 day share price return decline, contrasts with its 3 year total shareholder return of 33.8% and 5 year total shareholder return of 41.9%...

If you are wondering whether Globus Medical's current share price offers fair value or not, the recent trading pattern gives you plenty to think about. The stock closed at US$83.51, with returns of a 4.2% decline over the last 7 days and a 12.5% decline over 30 days, while still sitting on a 14.1% gain over 1 year, 46.7% over 3 years and 33.0% over 5 years. Recent news coverage has focused on Globus Medical's position in the medical devices space and how its product portfolio fits into long...

In March 2026, Century Aluminum announced that Levi Chaffin has been promoted to Senior Vice President of Operations, Americas, overseeing its U.S. and Jamaican operations after previously managing the Sebree smelter and its roughly 650-person workforce. This internal promotion places an operations-focused leader with deep engineering, reliability, and process-improvement credentials at the center of Century’s Americas footprint, potentially sharpening execution across its key assets. Next,...

Nu Holdings (NYSE:NU) has drawn investor attention after recent share price pressure, with the stock down about 10% over the past month and nearly 20% in the past 3 months. See our latest analysis for Nu Holdings. While the recent 30-day share price return of about a 10% decline and year-to-date share price return of about a 21% decline suggest fading short-term momentum, the 1-year and 3-year total shareholder returns of about 32% and about 3x show that longer-term holders have still seen...

Astrana Health, Inc. recently filed two shelf registrations, including a US$120.95 million ESOP-related offering for 5,000,000 common shares and a broad omnibus shelf covering common and preferred stock, debt, warrants, and other securities. This expanded financing toolkit gives Astrana Health more flexibility to issue different types of securities, potentially reshaping its capital structure and funding options for future growth initiatives. Next, we'll examine how this expanded shelf...

Exelon (EXC) is back on some investors’ radar after recent trading, with the stock last closing at $49.11. That price sits against a mixed pattern of short and longer term total returns. See our latest analysis for Exelon. Recent trading has added to Exelon’s 11.82% year to date share price return and 12.66% 90 day share price return. Longer term total shareholder returns of 10.75% over 1 year and 84.27% over 5 years indicate steady compounding. If you are comparing Exelon with other...

If you are looking at Halozyme Therapeutics and wondering whether the current share price reflects its true worth, this breakdown will help you make sense of what you are paying for. The stock recently closed at US$62.13, with returns of 1.2% decline over 7 days, 10.6% decline over 30 days, 11.6% decline year to date and 2.6% decline over 1 year, set against gains of 60.4% over 3 years and 44.7% over 5 years. Recent coverage has focused on how the share price has moved over different time...